ClinicalTrials.gg
Not yet recruitingNCT07161843QRX3 in ARFUpdated Feb 18, 2026

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

A Phase 2/3 interventional study of QRX-3 in Acute Renal Failure (ARF) and Acute Tubular Necrosis, sponsored by Ebima Clifford Okundaye. Not yet recruiting at 1 site in United States. Open to participants aged 10 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Ebima Clifford Okundaye · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
10 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
41st of 237
500 · median 67
Started
2026
with 28 others
Phase 2/3
9 of 370
4 open now
Primary completion
2026-12
later than 22 of 87 live
Registered
334th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 41st largest by planned enrollment of the 237 interventional ones that give a count, is one of 29 that started in 2026, is one of 9 in phase 2/3, reaches primary completion later than 22 of the 87 other live ones, and was the 334th registered.

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 10 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

03

Conditions studied

  • Acute Renal Failure (ARF)
  • Acute Tubular Necrosis

Browse trials for

Keywords

  • acute renal failure
  • acute tubular necrosis
04

Who can participate

Ages eligible
10 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients
  • presence of Acute renal failure
  • Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of >2%
  • willingness to participate

Exclusion criteria

Exclusion Criteria:

High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Use of QRX-3 in addition to standard therapy

    QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days

    Drug: QRX-3

  • Placebo comparator
    control group

    placebo twice daily will be given to this group in addition to standard therapy

    Drug: QRX-3

Interventions

  • DrugQRX-3

    Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

    Also known as: Eseronate

06

What researchers measure

Primary outcomes

  1. Rate of change in creatinine glomerular filtration rate

    compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients

    Time frame: 28 days

Secondary outcomes

  1. daily change in glomerular filtration rate in ml/min

    daily change in GFR by creatinine in mls/min

    Time frame: 7 days

  2. daily change in cystatin C level in mg/dl

    daily change in measured cystatin C level

    Time frame: 7 days

Other outcomes

  1. effect of QRX-3 on recovery of renal function in patients with ATN renal failure

    comparism of number of patient achieving return to baseline renal function in both groups

    Time frame: 28

07

Study locations

1 site
  • Neukidney Inc
    Rosharon, Texas 77583, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Sep 9, 2025
StartEst.
Jun 30, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Feb 1, 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07161843
Lead sponsor
Ebima Clifford Okundaye
Responsible party
Ebima Clifford Okundaye (President, Neukidney Inc.) — Sponsor-investigator
First posted
Sep 9, 2025
Start date
Jun 30, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Ebima Okundaye, MD
Contact
cliffordebima@gmail.com
9738855457

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion